Key risk factors for CNS involvement in AML include complex karyotypes, AML relapse, FAB M5 classification, high LDH levels (Lactate Dehydrogenase A, LDHA), the presence of other extramedullary AML manifestations, and FLT3-ITD mutations [221]. This evidence concerns the gene FLT3 and acute myeloid leukemia.